Clinical and laboratory features of AITL
| Publications reviewed . | 1975 to 1999* . | 2007 to 2016* . |
|---|---|---|
| ATIL cases reviewed | 77 | 556 |
| Males, % | 42-48 | 56-74 |
| Median age range | 62-68 | 62-65 |
| General clinical features, % | ||
| B-symptoms | 29-85 | 55-77 |
| Performance status >1 | 57 | 37-50 |
| LDH elevation | 25-74 | 60-86 |
| Advanced stage (III/IV) | 94 | 81-92 |
| Low-risk IPI (0-1) | No reported | 11-21 |
| Areas of involvement, % | ||
| Multiple nodal stations | 97-100 | 76-99 |
| Bone marrow | 61 | 28-70 |
| Skin rash | 38-48 | 31-45 |
| Laboratory tests, % | ||
| Anemia | 40-83 | 33-65 |
| Positive DAT (Coomb’s) | 43-57 | 13-75 |
| Thrombocytopenia | 9 | 20-31 |
| Hypergammaglobulinemia | 50-77 | 50-84 |
| Hypereosinophilia | 29-39 | 32-34 |
| Publications reviewed . | 1975 to 1999* . | 2007 to 2016* . |
|---|---|---|
| ATIL cases reviewed | 77 | 556 |
| Males, % | 42-48 | 56-74 |
| Median age range | 62-68 | 62-65 |
| General clinical features, % | ||
| B-symptoms | 29-85 | 55-77 |
| Performance status >1 | 57 | 37-50 |
| LDH elevation | 25-74 | 60-86 |
| Advanced stage (III/IV) | 94 | 81-92 |
| Low-risk IPI (0-1) | No reported | 11-21 |
| Areas of involvement, % | ||
| Multiple nodal stations | 97-100 | 76-99 |
| Bone marrow | 61 | 28-70 |
| Skin rash | 38-48 | 31-45 |
| Laboratory tests, % | ||
| Anemia | 40-83 | 33-65 |
| Positive DAT (Coomb’s) | 43-57 | 13-75 |
| Thrombocytopenia | 9 | 20-31 |
| Hypergammaglobulinemia | 50-77 | 50-84 |
| Hypereosinophilia | 29-39 | 32-34 |
DAT, direct anti-globulin test; IPI, International Prognostic Index; LDH, lactate dehydrogenase.
Article referenced in reference section; not all parameters were recorded for all patients.